Skip to main content
AbbVieInvestment

PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology

Source: Autobound Signal API · 112 signals tracked for AbbVie · updated

Get AbbVie's live signals in Claude or ChatGPT, or by API

AskWhat changed at AbbVie this week? Use Autobound signals for abbvie.com.

What happened

AbbVie Ventures participated as a new investor in PsiThera's $25 million financing round, with Managing Director Claire Leurent joining PsiThera's Board of Directors.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

AbbVie Ventures and Lumination Capital joining existing lead investors Samsara BioCapital and Lightstone Ventures Financing supports TNFα development candidate nomination and initiation of IND-enabling studies, alongside advancement of oral TL1A inhibitors into lead optimization Proprietary QUAISAR platform, combined with approach to Physical AI, continues to drive rapid design of optimized oral drug candidates WATERTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PsiThera, a biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases, today announced the closing of a $25 million financing. New investors AbbVie Ventures and Lumination Capital participated, along with existing lead investors Samsara BioCapital and Lightstone Ventures, and other existing investors. In connection with the financing, Claire Leurent, Ph.D., MBA, Managing Director at AbbVie Ventures, has joined PsiThera's Board of Directors. Proceeds from the financing are expected to fund operations, supporting development candidate nomination and the initiation of IND-enabling studies for the company's lead oral small molecule TNFα inhibitor, as well as advancement of its oral TL1A program into lead optimization. The company's proprietary QUAISAR platform combines physics-based molecular simulation, machine...

Keep reading with a free account

The rest of this article, and every signal for AbbVie, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Investment

What this signalsAn investment often shows where the company plans to grow.

Takes effect
Nov 10, 2026
Location
Watertown, Massachusetts, United States

Companies

  • PsiTheraRelated companypsithera.com

More investment signals at other companies

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Nov 10, 2026
signal_type
news
signal_subtype
invests_into

Use this data

Get every investment signal for AbbVie and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”

  2. Send it to your own tools

    The Signal API returns investment signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5bb7a7c5-b4ec-13fe-eae5-e2e5360153dd returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.

{
  "signal_id": "5bb7a7c5-b4ec-13fe-eae5-e2e5360153dd",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-11-10T12:00:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/11/10/3399296/0/en/psithera-closes-25-million-financing-to-advance-oral-therapeutics-in-immunology.html",
    "title": "PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology",
    "excerpt": "AbbVie Ventures and Lumination Capital joining existing lead investors Samsara BioCapital and Lightstone Ventures Financing supports TNFα development candidate nomination and initiation of IND-enabling studies, alongside advancement of oral TL1A inhibitors into lead optimization Proprietary QUAISAR platform, combined with approach to Physical AI, continues to drive rapid design of optimized oral drug candidates WATERTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PsiThera, a biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases, today announced the closing of a $25 million financing. New investors AbbVie Ventures and Lumination Capital participated, along with existing lead investors Samsara BioCapital and Lightstone Ventures, and other existing investors. In connection with the financing, Claire Leurent, Ph.D., MBA, Managing Director at AbbVie Ventures, has joined PsiThera’s Board of Directors. Proceeds from the financing are expected to fund operations, supporting development candidate nomination and the initiation of IND-enabling studies for the company’s lead oral small molecule TNFα inhibitor, as well as advancement of its oral TL1A program into lead optimization. The company’s proprietary QUAISAR platform combines physics-based molecular simulation, machine...",
    "summary": "AbbVie Ventures participated as a new investor in PsiThera's $25 million financing round, with Managing Director Claire Leurent joining PsiThera's Board of Directors.",
    "location": "Watertown, Massachusetts, United States",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/826052f2-bc15-4f56-a532-e03dff97934d",
    "confidence": 0.9,
    "published_at": "2026-11-10T12:00:00Z",
    "location_data": [
      {
        "city": "Watertown",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-10",
    "article_sentence": "In connection with the financing, Claire Leurent, Ph.D., MBA, Managing Director at AbbVie Ventures, has joined PsiThera’s Board of Directors.",
    "related_company_name": "PsiThera",
    "related_company_domain": "psithera.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.